Tubulis, a Munich-based biotech leader in targeted cancer therapies, and Mindpeak, a Hamburg-born innovator in AI-powered pathology solutions, have entered into a collaborative agreement to jointly explore new opportunities at the intersection of biotechnology and artificial intelligence.

Tubulis is at the forefront of developing next-generation antibody-drug conjugates (ADCs), precision medicines that combine targeting antibodies with potent drug payloads to destroy cancer cells while sparing healthy tissue. The company recently completed a record-setting Series C financing round of over €300 million - one of the largest ever raised by a private European biotech

Mindpeak brings deep expertise in artificial intelligence for digital pathology, with a mission to empower pathologists and clinical labs with tools that improve speed, reproducibility and diagnostic confidence. Mindpeak’s AI algorithms are designed to automate complex tissue image analysis, enabling more precise characterization of cancer biomarkers - a critical step in both routine diagnosis and biomarker-driven therapy selection.

Through this collaboration, Tubulis and Mindpeak aim to align their complementary strengths in biopharma innovation and AI-driven diagnostics to explore integrated solutions that can enhance patient stratification, support clinical decision-making and ultimately improve outcomes in oncology. This partnership reflects a shared commitment to pushing the boundaries of what precision medicine can deliver and accelerating the translation of scientific advances into clinical impact.

‍